QNTM — Quantum BioPharma Income Statement
0.000.00%
Last trade - 00:00
- CA$11.58m
- CA$6.88m
- 23
- 44
- 14
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.194 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | -1.3 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 27.8 | 30.7 | 33.7 | 27.4 | 23.8 |
Operating Profit | -27.6 | -30.7 | -33.7 | -27.4 | -23.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -39.2 | -28.5 | -33.9 | -26.7 | -18.2 |
Net Income After Taxes | -39.2 | -28.5 | -33.9 | -26.7 | -18.2 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -39.2 | -31.8 | -35.3 | -23.6 | -18.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -39.2 | -31.8 | -35.3 | -23.6 | -18.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -355 | -149 | -63.1 | -44.8 | -22.5 |